Hot FDA Trade: BioDelivery Sciences International
Michael Vlaicu (June 13th, 2009) Writes:
BioDelivery Sciences International
(NASDAQ:BDSI)
Continuing with the trend of pre-FDA decision BioPharma companies, StocksHaven Investments takes a closer look at BDSI which hopes it’s product Onsolis will strive past approval and make its way onto shelves world-wide.
About BDSI: BioDelivery Sciences International, Inc. is a specialty pharmaceutical company that is utilizing licensed and owned drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, significant new formulations of proven therapeutics. Utilizing its drug delivery technologies, the Company is developing formulations of pharmaceuticals aimed at acute (short term) conditions occurring in patients, mostly notably in the areas of pain and fungal infections.
Onsolis: BDSI®’s first application of the lead BEMA™ technology is Onsolis™ (fentanyl buccal soluble film). Onsolis™ utilizes the BioErodible MucoAdhesive (BEMA®) drug delivery technology, which consists of a small, bioerodible polymer
...2008 Beijing Olympic Games;, BEMA™ technology;, BioDelivery Sciences International Inc.;, Datamonitor;, drug delivery technologies, Drug Delivery Technology, Europe, European Union, Fda, Fuels Bank;, Hot FDA Trade;, Market Commentary, Meda Ab, Michael Vlaicu;, North America, ONSOLIS;, owned drug delivery ;, owned drug delivery technologies;, pain, Pharmaceutical, Pharmaceuticals, south korea, Stocks to Watch, StocksHaven Investments;, Taiwan, United States, USD


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)


